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Abstract
Background: Invasive Occipital Nerve Stimulation (iONS) is a costly technique which appears effective in drug-refractory
chronic cluster headache (drCCH) management. Available data on long-term effectiveness and safety of iONS
in this indication are scarce, though they could be useful to neurologists and patients in daily practice. The
purpose of this short report is to discuss the very long-term outcome of a drCCH cohort, including adverse events.
Findings: Previously, favourable results were obtained with iONS in 15 drCCH patients: 80 % were significantly
improved and 60 % were pain free. We report here the very long-term follow-up (up to nine years) of 10 patients
belonging to this cohort. Meanwhile 5 patients had to be definitively explanted because of device infection (3) or
paresthesia intolerance (2). Four patients (40 %) evolved to an episodic form of CH. Six remained chronic but their
attack frequency was decreased by 70 % on average. Intake of preventive drugs is still necessary in 80 % of patients.
All patients needed at least one battery replacement.
Conclusions: Up to nine years after implantation, iONS is still effective in most patients with drCCH. Concomitant
preventive drugs remain often necessary. Forty percent of patients reverse to episodic CH, possibly by natural history.
iONS is not a benign procedure but device-related complications appear similar to those reported with other invasive
neurostimulators.
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Introduction
Cluster headache (CH), especially its chronic form (see
[1] for definition), is among the most disabling primary
headaches. A small percentage of chronic cluster head-
ache patients (CCH) do not respond to or do not tolerate
existing preventive drugs and are considered as drug-
resistant (drCCH, [2]). In the last decades various non-
pharmacological therapeutic strategies have been applied
to relieve these patients, among them invasive Occipital
Nerve Stimulation (iONS, [3–8]) that provided middle-
term results similar to those of the more invasive and risky
hypothalamic deep brain stimulation (hDBS, [9–11]). We
published previously a prospective trial of iONS involving
15 drCCH patients [5]. One patient had an immediate de-
vice infection and could not be evaluated. After 36 months
on average, 11 of the 14 remaining patients (~80 %) had
an improvement of at least 90 % in attack frequency,
whereas 60 % became pain-free for long time periods.
Two patients did not respond or described mild improve-
ment. Up to now, no sham-controlled study of iONS is
available in drCCH, but a large trial is ongoing [12].
Recently, Leone et al. [11] published the very long-
term outcome (median 8.7 years) of 17 drCCH patients
treated with hDBS, and found out that 35 % were still
almost pain-free (i.e. less than one attack every three
months) whereas another 35 % reversed to an episodic
cluster pattern. Unfortunately such data are not available
for drCCH patients treated with iONS.
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Along the same line, we thus aimed to share some
relevant information about the long-term clinical useful-
ness and especially the risks of this costly procedure, for
both neurologists and patients, based on our experience
of nearly nine years.
Summary of methods
The complete report of the methods and surgical procedure
were described elsewhere [3, 5]. Our cohort initially in-
cluded 15 drCCH patients with side-locked attacks from the
start (Fig. 1, see flowchart, one woman, average age at
implantation 47.6 ± 9.6 years, duration of the chronic phase
7 ± 4.2 years). In six of them, cluster headache had been
chronic from the onset. All subjects gave written informed
consent and the study was approved by the Local Ethics
Committee, CHR Citadelle, Liège, Belgium. iONS (2005–
2009) was performed only on the headache side, using a
paddle-style stimulating lead with 4 distal electrodes (Med-
tronic 3587A Resume II®; Medtronic, Minneapolis, MN,
USA) [3]. We used either Medtronic Itrel 3® or Medtronic
Synergy® stimulators, and six patients received subsequently
a rechargeable Medtronic Restore® when their first battery
was empty. The stimulation parameters were adjusted to
produce paraesthesia over the greater occipital nerve (GON)
territory, covering the largest area of the C2 dermatome.
Findings
The outcome of the 15 drCCH patients up to 8.6 years
after implantation is summarized in Table 1. Five out of
15 patients had their stimulator removed (33 %). Two
patients were explanted because they did not tolerate
the paraesthesia (at 4 and 35 months, 14 %), although
one of them was improved and evolved to an episodic
CH. This patient had been chronic from the onset, but
remained episodic after iONS removal. Besides the imme-
diate infection in one patient (see Introduction), three
more patients were subsequently explanted because of a
delayed infection (at 24, 38 and 53 months, 21 %, total rate
of infections 27 %). In one of them the attack frequency
increased dramatically afterwards, and he was thus reim-
planted 10 months later.
The remaining 10 patients have a mean follow-up of
71 months (Table 1, range 54–103). CH attacks recurred
in all patients who were pain-free at the previous middle-
term follow-up. In four patients (40 %), attacks relapsed
following an episodic pattern. The bouts responded to
standard preventive therapies (suboccipital steroid infiltra-
tion, verapamil …). The other six patients (60 %) became
chronic again [1] with an mean attack frequency ranging
from 3 to 30 per month, which represents a reduction of
70.8 % on average, compared to baseline (Table 1). How-
ever, 8/10 patients (80 %) still need preventive medications
but only 5/10 (50 %) are still stimulated (two are episodic
and three chronic). Their main explanation to discontinue
iONS was their improvement which persisted despite an
interruption of the stimulation due to various reasons
(cancer, empty battery…). Overall, compared to baseline
period, 9/10 patients have at least a 50 % decrease of
attack frequency. Six are satisfied with the treatment. The
need for repeated surgery is the main reason for patient’s
pONS implantation (2005-2009)
N=15 patients with refractory chronic CH
(Magis et al. Lancet Neurol 2007)
Middle-term follow-up (mean 36 months)
N=14

















* Of the 3 patients with delayed infections requiring explantation, 1 was reimplanted 10 months later




Fig. 1 Flowchart of the long-term follow-up. CH = cluster headache
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Technical problems iONS Satisfaction
1 50 E 9 4 0.29 N/A N/A N/A Verapamil N/A Unbearable
paresthesias: explanted




2 53 E 3 103 4.7 0.43 0.33 −93.00 % Verapamil Melatonine Lithium carbonate
Verapamil
Empty battery: ×3 ON Satisfied
3 51 E 7 102 3.84 0 0.1 −97.40 % Lithium carbonate
Verapamil
None Empty battery: ×4
Lead migration: ×1
ON Very satisfied









5 57 E 4 38 0.16 0 N/A N/A Verapamil N/A Delayed infection:
explanted
N/A Not available








7 63 E 5 95 1.00 0 0.17 −83.00 % Methysergide Lithium
carbonate
Lithium carbonate Empty battery: ×3 ON Satisfied
8 51 E 3 83 4.00 0 1 −75.00 % Verapamil
Methylprednisolone
None Empty battery: ×1 OFF Not satisfied










10 33 E 5 68 2.00 0 Episodic Episodic Verapamil Verapamil Gabapentine Empty battery: ×1 ON Satisfied
11 46 C 2 64 0.57 0.5 0.54 −5.26 % Verapamil Lithium
carbonate Gabapentine
Escitalopram





12 34 E 8 na na na N/A N/A Methylprednisolone N/A Immediate device
infection: explanted
N/A N/A




Empty battery: ×1 OFF Not satisfied
14 55 C 2 57 5.5 0 Episodic Episodic Methylprednisolone
Methysergide
Clomipramine
GON injection Verapamil Empty battery: ×1 OFF Not satisfied






















dissatisfaction. Hence, patients stimulated at long-term had
to undergo at least one additional surgery for battery re-
placement (up to four/patient). Two patients also needed
surgery for lead migration (2/10: 20 %). Some transient
attack side-shifts (a single bout or isolated attacks) had
been observed previously in nearly 30 % of patients, but
were not reported during the subsequent follow-up.
Discussion
Our data confirms that iONS is able to provide a long-
lasting relief in a majority of drCCH patients nearly
10 years after implantation.
All patients stimulated at long-term underwent at least
one additional surgery for battery replacement, but the
stimulators implanted initially had a limited lifetime and
were expected to deplete after a time period depending
on the stimulation intensity. Thus, a rechargeable device
was placed subsequently to ensure a longer-lasting stimula-
tion. Fifty-three percent of patients developed iONS-related
complications, like immediate or delayed infections which
finally required explantation of nearly 30 % of patients.
Besides the small size of our sample which could have
biased the results, this high number of adverse events can
be explained by several factors. First, the duration of our
follow-up period is exceptionally long. The cumulated rate
of adverse events probably increased with time and surger-
ies (especially repeated device replacements). Second, few
similar safety data are available in the literature. A high
complication rate was reported in chronic migraine patients
treated with iONS [13]. In a cohort of 157 patients, after
1 year follow-up only, the authors recorded 183 device/
procedure-related adverse events, among which 8.6 %
required hospitalisation. Overall 32.5 % of patients needed
additional surgery; 16.6 % had lead migration, 6.4 %
infection, 4.5 % skin erosion and 18 % local pain or
numbness. Besides the rare but possibly fatal risk of intra-
cerebral haemorrhage, hypothalamic deep brain stimula-
tion (hDBS), has similar long-term complications such as
infections (5/18, 1 immediate, 28 %), electrode migration
(2/17, 12 %), or need for battery replacement (6/17, 35 %)
[11]. Larger long-term data are available for invasive vagus
nerve stimulation in intractable epilepsy, and authors re-
port side effects in 50 % of patients, with surgical compli-
cations in 21 % [14].
Our clinical data support that iONS is no more than a
symptomatic therapy, as suggested before by other clin-
ical [3] and neuroradiological [15] observations. iONS
likely induces slow neuroplastic changes within non-
specific pain-control systems [3], which explains its bene-
ficial effects in various headache types. The evolution of
our patients was characterized by a sustained pain relief,
even in some patients who had discontinued iONS (see
Findings section). Forty patients became episodic and
60 % stayed chronic, but many still needed a concomitant
drug prophylaxis. With hDBS, after a similar follow-up
time, 35 % of drCCH patients remained ‘almost’ pain-free
[11], but the chronic phase duration, which could mirror
the disease severity, was on average twice longer in our
population (seven years vs. three years for hDBS). How-
ever, comparing the outcomes of both techniques is
challenging due to the small size of the series [11]. Inter-
estingly, three patients who had been chronic from CH
onset developed an episodic form after an initial pain-free
period under iONS. A similar evolution from a pain-free
state to an episodic form of CH has been described under
hDBS in 35 % of patients (6/17) [11], however they were
still stimulated; whereas the stimulator was turned off in
the half of our population. Leone et al. suggested that
hDBS might have changed the course of the illness by act-
ing on circuits involved in disease chronification [11]. We
have reported before that iONS applied during several
months modulated central areas involved in non-specific
pain control but did not modify the hypothalamic hyper-
metabolism found in CH [15]. It is also known that about
32 % of “primary” CCH patients can spontaneously evolve
to a “secondary” episodic type [16]. Thus, the emergence
of an episodic pattern after iONS could either be due to
the natural course of the disease, or be favoured by iONS.
In this trial, iONS had been performed unilaterally
(headache side), in patients with strictly side-locked
attacks. We previously observed a headache side shift
in 4 patients [3, 5], but the latter was transient and
fortunately did not recur at long-term. To avoid a possible
attack side shift associated with chronification a bilateral
stimulation is now proposed in drCCH patients.
Conclusion
Available open studies using iONS as add-on therapy
have provided encouraging results in drCCH, and iONS
is now recommended before considering the more risky
hDBS [17]. The very long-term evolution of patients
treated with this technique is unknown.though, but this
missing information is important for both neurologists
and patients when considering invasive neurostimulation.
Based on a 9-year experience, our data show that iONS
remains very effective in patients who had initially benefit-
ted from the procedure. That iONS did not prevent any
relapse confirms its purely symptomatic effect on pain-
controlling centres. Over time 40 % of patients reversed to
an episodic pattern of CH, perhaps by natural history.
This proportion is actually similar to the rate found in
medically-treated CCH patients [15], but the cohort stud-
ied here involved a subset of the most severely ill drCCH
sufferers, some of them being in chronic phase for several
dozens of years. The treatment could thus have modified
the course of the disease through a slow neuromodulation
phenomenon.
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Like other invasive neurostimulation techniques, iONS
is not harmless and its use in drCCH patients should be
considered carefully. Adverse events occurred in about
50 % of the subjects over time, but does not seem to
deviate significantly from cumulated rates described with
other techniques at very long-term (hDBS and VNS).
The refinement of surgical techniques and devices will
probably reduce the hardware-related complications. It
is also strongly suggested to refer patients to trained
surgeons who are familiar with iONS placement [13].
Patients must be aware that additional surgeries may be
needed to replace empty batteries (also rechargeable
batteries have a limited lifetime).
At present, because less risky than hDBS, iONS is
recommended to the most disabled drCCH patients
when invasive neurostimulation is considered. If available,
non-invasive neurostimulation devices like vagus nerve
[18] or transcranial direct current stimulators should be
tried before performing invasive procedures (see European
Headache Federation Statement [17]).
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